Current stock page

Catalysts

ACAD Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Oct 21, 2026

ACADAcadia Pharmaceuticals Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

NeutralEdge 9/10
$20.19−$0.25 (−1.22%)

Latest quote

  • Momentum
    45
  • Value
    57
  • Quality
    92
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Oct 21, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 4, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 65/100

Momentum 45/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Oct 21, 2026 · Sentiment 19.47%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 45/100AIQ Edge 9/10 Strong Relative Position
Beat rate
75%
3 of 4 reported periods
Average surprise
+345.5%
Across covered historical reports
Latest result
+164.1%
Aug 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$0.21——$332.29M—
Aug 4, 2026—$0.07$0.18+164.1%$296.55M$307.96M
May 6, 2026—$0.04$0.02-50.0%$280.25M$268.1M
Feb 25, 2026—$0.14$1.60+1067.9%$292.79M$283.99M
Nov 5, 2025—$0.14$0.42+200.0%$276.54M$278.63M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
15
Buy
5
Hold
1
Sell
12-month analyst target
$32.97
+63.30% versus current price
Based on 11 analyst observations. Targets are estimates, not predictions.
Low target
$14.50
-28.18% vs latest price
Average target
$32.97
+63.30% vs latest price
High target
$49.00
+142.69% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 4, 2026

Next known earnings or reporting date.

EPS estimate$0.20

Current analyst expectation for the upcoming report.

Revenue estimate$332.58M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score45

Where event reaction would show up first.

AIQ score65/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
11
Average target
$32.97
Target upside
63.30%
Target range
$14.50 - $49.00
90-day revisions
9

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
gurufocus.com · Oct 19, 2026

ACAD Reiterated by Needham -- Price Target Maintained at $35

Acadia Pharmaceuticals: Analyst Rating Update and Valuation Insights On October 19, 2026, Acadia Pharmaceuticals (ACAD) received a rating update from Needham

gurufocus.com · Oct 13, 2026

ACAD Downgraded by UBS -- Price Target Lowered to $23.00

Acadia Pharmaceuticals (ACAD) Downgraded by UBS: A Data-Driven Analysis On October 8, 2026, UBS has downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neut

gurufocus.com · Oct 5, 2026

Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook

On October 05, 2026, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the settlement of its patent litigation with Zydus concerning its flagship drug Nuplazi

gurufocus.com · Oct 5, 2026

Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent Lawsuits Ahead of Nuplazid Trial

On October 05, 2026, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and generic drug manufacturer Zydus jointly requested dismissal of all lawsuits and counterclaims

gurufocus.com · Sep 28, 2026

Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent

On September 28, 2026, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced it has received a Notice of Allowance from the United States Patent and Trademark Off

Open full news and sentiment

ACAD Catalysts FAQ

What are the next catalysts for ACAD stock?

ACAD's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ACAD stock?

Upcoming events that could move ACAD include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ACAD's next earnings report affect the stock?

ACAD's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ACAD stock higher?

ACAD could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ACAD stock?

ACAD could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.